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Abstract
Background: Frequent chronic obstructive pulmonary disease (COPD) exacerbation is a major cause of hospital
admission and mortality. It has been reported that Traditional Chinese Medicine (TCM) may relieve COPD
symptoms and reduce the incidence of COPD exacerbations, thus improving life quality of COPD patients. The
acute exacerbation of COPD risk-window (AECOPD-RW) is the period after an exacerbation and before the patient
returns to baseline. In the AECOPD-RW, patients are usually at increased risk of a second exacerbation, which may
lead to hospital admission and high mortality. It may be beneficial for acute exacerbation of chronic obstructive
pulmonary disease (AECOPD) patients to receive interventions during AECOPD-RW. During exacerbations the
treatment principle is to eliminate exogenous pathogens, whereas the AECOPD-RW treatment principle focuses on
enhancing body resistance.
Methods/Design: A prospective, multi-center, single-blinded, double-dummy and randomized controlled clinical
trial is being conducted to test the therapeutic effects of a sequential two stage treatment, which includes
eliminating pathogen and strengthening vital qi with syndrome differentiation. A total of 364 patients will be
enrolled in this study with 182 in each treatment group (TCM and control). Patients received medication (or
control) according to their assigned group. TCM for AECOPD were administered twice daily to patients with
AECOPD over 7 to 21 days, followed by TCM for AECOPD-RW over 28 days. All patients were followed for six
months. The clinical symptoms, the modified medical research council dyspnea (MMRC) scale and exacerbations
were used as the primary outcome measures. Pulmonary function, quality of life and mortality rate were used as
secondary outcome measures.
Discussion: It is hypothesized that sequentially eliminating pathogens and strengthening vital qi treatments with
syndrome differentiation will have beneficial effects on reducing the frequency and duration of acute exacerbation,
relieving symptoms and improving quality of life for COPD patients.
Trial registration: This study is registered at ClinicalTrials.gov, ChiCTR-TRC-11001460.
Keywords: Chronic obstructive pulmonary disease, Exacerbations, Traditional Chinese Medicine, Treatment, Clinical
trials
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by acceleration in the normal decline in lung func-
tion with age and by repeated exacerbations. These
exacerbations are associated with worsening symptoms
and lung function [1]. The frequency of exacerbation has
been shown to be an important determinant of the
impaired health-related quality of life seen in COPD
patients [2] and to affect decline in lung function [3].
Exacerbations are a frequent cause of physician consulta-
tion in primary and secondary care and a major cause of
hospital admission and death [4]. Therefore, the manage-
ment of exacerbations places a considerable burden on the
health services both in terms of physician consultation
time and healthcare cost [5]. A reduction in exacerbation
frequency would have a number of benefits for patients
and health services alike [6]. Therefore, preventing exacer-
bations is a key treatment goal.
The global initiative for chronic obstructive lung dis-
eases (GOLD) document suggests a follow-up at four to
six weeks after a hospitalized exacerbation [7]. However,
there is evidence that exacerbations tend to cluster in
time, with a high-risk period of recurrence during the
eight weeks following the first exacerbation [8]. This has
important implications for the target of preventative inter-
ventions. Therefore, from our clinical observation, we
have identified an acute exacerbation of chronic obstruc-
tive pulmonary disease risk-window (AECOPD-RW); that
is the period after a first exacerbation and before the
patient has returned to baseline. During this period,
although major symptoms have been relieved, lung func-
tion has not gone back to stable baseline, and inflamma-
tion may also continue. Therefore, patients may be at
increased risk of a second exacerbation, leading to hospital
admission and a high mortality rate. Thus, it seems appro-
priate to intervene in the AECOPD-RW.
Traditional Chinese medicine (TCM) is commonly used
for COPD in Asia. It has long been known that TCM is
effective in relieving symptoms, reducing the incidence of
COPD exacerbations and improving quality of life in
COPD patients.
Our previous study showed that in an exacerbation per-
iod the treatment principle was to eliminate exogenous
pathogens. When the patient enters the AECOPD-RW, the
treatment principle should be supporting body resistance
[9].
Our hypothesis was that a sequential TCM treatment
a i m e da te l i m i n a t i n gp a t h o g e n sa n ds t r e n g t h e n i n gv i t a l
qi with syndrome differentiation may reduce exacerba-
tion frequency in patients with AECOPD. In this paper,
we report the protocol on a multi-center, randomized,
single-blind, placebo-controlled trial to test this
hypothesis.
Objective
The objective is to determine whether sequentially elim-
inating pathogens and strengthening vital qi treatment
with syndrome differentiation reduces COPD exacerba-
tion frequency.
Methods and design
Study design
This clinical trial is multi-centered, randomized, single-
blind and placebo-controlled. The design of the study
integrates rigorous, contemporary clinical research meth-
odology in accord with principles set out in the Declara-
tion of Helsinki and the Good Clinical Practice guidelines
regarding the appropriate use of TCM in clinical practice.
Reporting will be guided by the CONSORT statement
[10,11]. Subjects are being enrolled at eight hospitals in
four sites in China: 1) The First Affiliated Hospital of
Henan University of TCM; 2) TCM hospital of Xinjiang
Uygur Autonomous Region; 3) Sichuan Province TCM
hospital; 4) Jiangsu Province Hospital of TCM; 5) the
First Affiliated Hospital of Henan University of Science
and Technology; 6) Henan University of Huaihe hospital;
7) The First Affiliated Hospital of Zhengzhou University;
and 8) Henan Provincial Chest Hospital. The eight hospi-
tals in China will randomly assign 364 patients with
AECOPD in a ratio of 1:1 to the TCM treatment group
or matching placebo. Consenting eligible participants will
be enrolled for five to eight weeks and required to attend
12 visits in total. The trial has three phases: one to three
weeks treatment with either TCM for AECOPD or
placebo granules, four weeks treatment with either TCM
for AECOPD-RW or placebo granules, and six months
follow-up (Figure 1).
Study duration
Ongoing recruitment will occur for a maximum period
of 18 months (between July 2011 and December 2012)
or until 364 individuals are randomized.
Subjects
A total of 364 participants will be recruited through local
advertising and doctor referrals from hospital outpatients
and general practice clinics. Interested participants can tel-
ephone or email the trial coordinators at the correspond-
ing sites for further information. Participant information
and consent forms will be sent to interested individuals to
be read prior to scheduling their first visit.
Inclusion criteria for participation in the trial
The inclusion criteria are as follows: 1) males and females
aged 40 to 80 years inclusive; 2) they must satisfy the
COPD diagnostic criteria defined by GOLD (post-
bronchodilator spirometry, forced expiratory volume in 1
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Page 2 of 7second (FEV1)/forced vital capacity (FVC) < 0.7 and pre-
dicted FEV1 50% to 80%); 3) they must experience an
acute infective exacerbation of COPD; 5) meet the TCM
diagnostic criteria (syndrome of exogenous cold-evil and
internalization, syndrome of accumulation of phlegm-
dampness in the lung, syndrome of phlegm-heat
obstructing in the lung); and 6) give written informed
consent to participate.
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Figure 1 Participation flow chart.
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Exclusion criteria include: 1) pregnancy, breast-feeding or
women intending to become pregnant during the course
of the study; 2) inability to understand the nature, scope
and possible consequences of the study; 3) diagnosis of
bronchiectasis or active tuberculosis, obliterative bronch-
iolitis or diffuse pantothcnic bronchiolitis, pneumothorax,
pleural effusion or pulmonary embolism; 4) a history of
bronchial asthma or neuromuscular disorder that affects
respiration; 5) cancer; 6) respiratory failure that needs
mechanical ventilation; 7) serious illnesses, such as heart,
liver or kidney diseases, or unstable hemodynamics; 8)
inability to adequately perform spirometry tests; 9) need
for long periods of bed rest; 10) on long-term immuno-
suppressive agents or immunostimulants; 11) an allergic
history to TCM products or participating in other trials.
This study will be conducted in accordance with protec-
tion of patients, as outlined in the Declaration of Helsinki.
Each participant will sign the written informed consent
before undergoing any examination or study procedure, in
compliance with Good Clinical Practice. Patients whose
syndrome differentiation of TCM is the syndrome of exo-
genous cold-evil and internalization, syndrome of accumu-
lation of phlegm-dampness in the lung or syndrome of
phlegm-heat obstructing in the lung are included. Patients
who initially meet eligibility criteria will complete the addi-
tional baseline testing and will be randomized into either
the treatment or the control group.
Ethics issue
This study has been approved by the Ethics Committee of
The First Affiliated Hospital of Henan University of TCM
(No: YFYKYLL2011-001). Each participating center
obtained a local Institutional Review Board Approval. All
study participants will sign the written informed consent
prior to participation.
Interventions
Eligible patients will be randomized to one of the two
arms: placebo or Chinese medical herb (11.65 g twice
daily). Three TCM formulas for exacerbation will be
administered orally for 7 to 21 days: sanhanhuayinfang
(Ephedra, Rumulus Ginnamomi, Rhizoma Zingiberis, and
so on), qingrehuatanfang (Mongolian snakegourd fruit,
Rhizoma Pinelliae, Bulbus Fritillariae Cirrhosae and so
on), zaoshihuatanfang (Prepared Pinellia Tuber, Officinal
Magnolia Bark, Tangerine Peel and so on). There are also
three TCM formulas for AECOPD-RW that will be admi-
nistered orally for four weeks; they are: bufeijianpifang
(Codonopsis, Astragalus root, Largehead Atractylodes
Rhizome, Perilla Fruit, Mangnolia officinalis,a n ds oo n ) ,
bufeiyishenfang (Ginseng, Astragalus root, medlar and so
on), yiqizishenfang (Ginseng, solomonseal, Rehmannia
Glutinosa and so on). All drugs were made into granules
by Jiangyin Tianjiang Pharmaceutical Co., Ltd. Jiangyin
city, Jiangsu province, China). In this study, the subjects
and statisticians will be blinded to treatment assignment.
In this respect, the trial is single-blind. Randomization of
subjects will occur centrally using a random number gen-
erator and will be stratified bys y n d r o m ed i f f e r e n t i a t i o n
of TCM. (Syndrome, as related to illnesses in Western
medicine, is composed of a set of signs and/or symptoms
classified by Traditional Chinese Medicine practitioners.
TCM Syndrome differentiation is based on symptoms
and helps to identify a subset of disease). Patients will
visit the doctor at one-, three- and six-month follow-ups.
Randomization and allocation
Treatment allocation occurs when the study participant
meets the inclusion criteria and signs the informed con-
sent form. The teletherapist will then register the partici-
pant into the database, which, in turn, asks if they are
ready to be randomized. After the teletherapist enters
Yes, the site-specific randomization program displays the
participant’s group assignment number (placebo versus
Chinese medical herb). Site-specific randomization lists
will be computer-generated (that is, generated by an indi-
vidualized basic visual code program) and concealed
from the researchers by a senior data manager, who is
not involved in the study. This information will remain
confidential and is not shared with the study sites, in
concordance with the CONSORT guidelines. This trial
uses a prospective, randomized, outcome-blinded design,
in which all outcome assessments are made by a research
assistant blinded to treatment allocation and uninvolved
in patient consent and management. The allocation list
will be protected by password access files and held by an
independent non-investigator .I nt h ee v e n to fac l i n i c a l
emergency, the individual’s randomization code and
group allocation can be identified.
Sample size
The sample size calculation is based on the effect size of
clinical symptom changes in AECOPD subjects from a
previous trial of one of the most commonly used TCM
injections [12]. In that study, the mean effective change
in clinical symptoms was 97% in the treatment group,
compared to 87% in the placebo group (P < 0.05). For
t h ep r o p o s e ds t u d y ,t oa c h i e v eas i m i l a rd i f f e r e n c e
between the TCM and placebo treatment groups with
an 90% power and a two-tailed significance level of 5%,
n1 = n2 =1 , 6 4 1 . 6×[ [ ] ]
2, the sample size in each group
is 145. Considering a 20% drop-out rate over the course
of the study, 182 patients will be enrolled in each group,
that is, 364 in total. Intention-to-treat analysis will be
applied to minimize bias due to drop-outs.
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Primary outcome measure
Exacerbations Frequency, nature and severity of exacer-
bations of COPD will be evaluated in the first, the third
and the sixth month during the follow-up period. If the
interval between two events of acute exacerbation is
within five days, it can be counted as one acute
exacerbation.
Respiratory symptoms are classified as “major” symp-
toms (dyspnea, sputum purulence, sputum amount) or
“minor” symptoms (wheezing, sore throat, cough, and
symptoms of a common cold which were nasal conges-
tion/discharge). Exacerbations are defined as the presence
for at least two consecutive days of an increase in any two
“major” symptoms or an increase in one “major” and one
“minor” symptom according to criteria modified from
Anthonisen and colleagues [13]. The first of the two con-
secutive days is taken as the day of onset of exacerbation.
We will also analyze recovery from exacerbation,
because in most clinical studies a patient not having an
exacerbation for four to six weeks would be considered
stable. The time to the onset of the next exacerbation is
defined as the number of days from onset of one exacerba-
tion to onset of the next exacerbation [1].
Symptoms and signs
Symptoms including cough, sputum, dyspnea, fever, acra-
tia, cyanosis, wheezing and respiratory rate, and so on, will
be evaluated on days 0 (admission), 4, 7, 14 and 21 during
the exacerbation period, each week during the AECOPD-
RW period, and in the first, the third and the sixth month
during the follow-up period.
Dyspnea
The modified medical research council dyspnea (MMRC)
scale, which was first developed by the British Medical
Research Council (MRC), and later revised by the Ameri-
can Thoracic Society (MMRC), will be observed and
recorded before treatment, each week during the treat-
ment period, and in the first, the third and the sixth
month during the follow-up period.
Secondary outcome measure
Secondary outcome measures include efficacy and safety
components
2.1 Quality of life (QoL): QoL assessed by the COPD
Assessment Test (CAT) will be observed and recorded
on Day 0 (admission), after exacerbation and after
AECOPD-RW during the treatment period, and in the
first, the third and the sixth month during the follow-up
period.
2.2 Lung function: Lung function using spirometry
indices of FEV1, FVC and FEV1/FVC ratio will be tested
and recorded on Day 0 (admission), after exacerbation
and after AECOPD-RW during the treatment period,
and in the third month during the follow-up period.
2.3 Mortality rate: All-cause mortality will be recorded
at the end of the sixth month during the follow-up
period.
Adverse event reporting
Routine calibration and standard operating procedures
will be uniformly undertaken at each site. Participants
will be advised not to use respiratory medications for
several hours prior to their spirometry testing. Two sets
of measurements will be taken at each visit, pre-bronch-
odilator and post-bronchodilator (post 400 μg of inhaled
Salbutamol).
Any adverse events will be listed in the trial record
and followed up to completion by the trial coordinators
and respiratory physicians. Adverse event details will be
scored using a six-point scale, 0 = none, 1 = minimal, 2
= mild, 3 = moderate, 4 = severe, and 5 = extremely
severe. Participants will be able to report adverse events
anytime throughout the trial and will receive advice
accordingly. Serious adverse events will be reported to
the reviewing HREC and site HRECs within the time-
frame specified by the lead HREC.
Throughout the study period trial coordinators will
contact the participant’s usual treating doctor to record
relevant data on presentations and exacerbations.
To assist with outcome documentation and medica-
tion compliance, participants will be given a participant
diary for the duration of the trial. They will be asked to
record trial medication and relief medication usage as
well as any new medications they commence during the
trial.
Participants may withdraw from the study for any reason
at any time without repercussion. They will only be with-
drawn by investigators if it is deemed medically unsafe for
them to continue. Dropouts will not be replaced.
Statistical analysis
A descriptive statistical analysis will be performed for all
study variables. We will calculate the mean, median and
standard deviations for quantitative variables, and the
absolute and relative frequency for qualitative variables.
We will use SPSS 19.0 (License number: 6f1d84c801f-
1e6010dc, SPSS Inc. Chicago, Illinois state, United States)
to statistically analyze the data. An intention-to-treat ana-
lysis will be applied using the Last Observation Carried
Forward (LOCF) method for missing data. Analysis of
covariance with baseline as covariate will be used to assess
differences in treatment outcomes between the two groups
at each of these time points. To correct for inflated risk of
Type 1 error, multiple comparison procedures suggested
by Ludbrook et al. will be used [14]. The use of relief med-
ication during the trial will be investigated for its effect on
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tistical analysis. A Data Safety Monitoring Board has been
established to assess the progress of the trial, particularly
safety endpoints.
Discussion
Chronic Obstructive Pulmonary Disease (COPD) remains
a major public health problem. Exacerbations of COPD
are an important cause of the considerable morbidity and
mortality found in COPD. The aim of AECOPD treatment
should be to decrease symptoms and exacerbations,
reduce the risk of hospital admission and increase lung
function and improve QoL. Recently, the approach to
therapy has focused on symptomatic relief.
Traditional Chinese Medicine (TCM), as a system of
medicine, has been a form of health care in China and its
neighboring countries for several thousand years. It has
been reported that TCM therapy, such as tanreqing injec-
tion, could improve the Chinese medical signs and symp-
toms in patients with AECOPD and improve airway
inflammation, airway mucus hypersecretion [15,16], and
lung function and relieve airway inflammation in patients
with stable COPD [17].
The recently updated “Global initiative for chronic
Obstructive Lung Disease” guidelines recognize that after
discharge from the hospital, care should provide for four-
to six-week follow-up assessment, with an absence of
exacerbation for four to six weeks being considered stable
[1]. More recently, data have emerged that the timing of a
second exacerbation after a first event is indeed nonran-
dom [8], and may relate to the therapy used. Therefore,
we introduce the concept of the AECOPD risk-window
(AECOPD-RW). That is, after a first exacerbation, before
the patient returns to stable baseline, despite relief of
major symptoms, poor lung function and inflammation
may persist. In this period, patients may be at increased
risk of a second exacerbation, which is responsible for hos-
pital admission and increased mortality. It seems appropri-
ate, therefore, to provide interventions for AECOPD-RW.
If patients are given TCM in addition to the usual treat-
ment during the AECOPD-RW period, it may resolve
COPD.
The study will be a large, multi-center, long-term trial of
chronic obstructive pulmonary disease, and the data gath-
ered will shed new light on traditional Chinese medicine
for COPD treatment.
Trial status
At the time of manuscript submission, we have recruited
105 patients but have not completed patient recruitment.
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